What is it about?
Rationale behind using local therapy in patients with oligometastatic non small cell lung cancer specially in setting of immunotherapy or targeted therapy
Featured Image
Why is it important?
Oligometastatsis either de novo or induced is increasingly being recognized in patients with NSCLC and there exists a cohort of patient that can be targeted with radiation to metastatic sites with a goal for cure and active surveillance.
Perspectives
We have exhaustively looked into the existing data of oligometastatic NSCLC patients who have been treated in prospective or retrospective manner with either SBRT or surgical resection. We have also discussed the rationale and opputrtunity to combine targeted therapy or immunotherapy with SBRT and the possible clinical trials that can be designed in future. We have also discussed the cost of SBRT in this patient population.
M.D. Pranshu Bansal
Univerity of new mexico cancer center
Read the Original
This page is a summary of: The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope, Future Oncology, December 2016, Future Medicine,
DOI: 10.2217/fon-2016-0219.
You can read the full text:
Contributors
The following have contributed to this page
